OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
The HCPLive surgery page is a resource for medical news and expert insights on invasive medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for surgery, and more.
March 10, 2023
An economic analysis suggests Medicare reimbursement for complex cataract surgery fails to cover increased costs required for the procedure and may affect practice patterns.
March 09, 2023
Gregg W. Stone, MD, discussed the 5-year findings of the COAPT trial and provided insight into the benefit of the transcatheter procedure in high-risk patients with heart failure.
February 27, 2023
Antibiotic use was not linked to a decrease in infectious complications in either the unadjusted analysis or the adjusted analysis.
February 12, 2023
David Tom Cooke, MD, reviewed the importance of shared decision making as it relates to risk and benefit of cancer screening, as well as in more refined invasive care options.
February 09, 2023
Cooke joins the first episode of 2023 to discuss his colleague’s specific role in lung cancer screening and intervention and advances to minimally invasive, robotic and bronchoscopic techniques.
February 01, 2023
The statement suggests PCI without surgery on site is as safe as PCI at centers with on-site surgery across randomized controlled trials, observational studies, and international experiences.
January 20, 2023
6-year results from the LiGHT trial suggest SLT is a safe treatment for eyes with open-angle glaucoma and ocular hypertension, providing drop-free IOP control.
January 18, 2023
Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture.
January 17, 2023
The TAVI system Navitor from Abbott is designed to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
January 12, 2023
At 12 months of the CAPLA trial, the addition of posterior wall isolation to pulmonary vein isolation led to no significant improvements in freedom from atrial arrhythmia.